ArticlePharmacology research & perspectives2024

Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance.

Naoki Okamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.